[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648063":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":33,"locations":33,"responsibleParty":34,"collaborators":33,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":33,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":62,"whyStopped":33,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":33},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Tirzepatide + Lifestyle Intervention","EXPERIMENTAL","Standardized lifestyle intervention and standard AF management plus once-weekly subcutaneous tirzepatide, initiated after randomization and continued through Week 52.\n\nTirzepatide titration (per NMPA label):\n\n* Weeks 1-4: 2.5 mg once weekly (initiation)\n* Weeks 5-16: escalate by 2.5 mg every 4 weeks (5 mg → 7.5 mg → 10 mg)\n* Weeks 17-52: maintenance 10 mg once weekly, up-titratable to 15 mg (maximum dose 15 mg)",[13,14],"Drug: Tirzepatide","Behavioral: Structured Lifestyle Intervention",{"label":16,"type":17,"description":18,"interventionNames":19},"Lifestyle Intervention","ACTIVE_COMPARATOR","AF Management and Post-Ablation Care\n\n* Ablation technique: circumferential pulmonary vein isolation (CPVI) ± adjunctive linear ablation at operator discretion, using established mapping and energy delivery protocols\n* Peri-procedural anticoagulation: guideline-directed anticoagulation\n* Antiarrhythmic drug (AAD) use: standardized per protocol SOP;\n\nExercise Intervention • Target: moderate-intensity aerobic exercise ≥150 minutes per week, OR vigorous-intensity aerobic exercise ≥75 minutes per week\n\nDietary Intervention\n\n• Caloric target: estimated total energy expenditure (TEE) minus 500 kcal\u002Fday\n\nOther Risk Factor Management\n\n* Smoking cessation\n* Alcohol restriction\n* Comorbidity management\n* OSA management",[14],[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tirzepatide","Dual GIP and GLP-1 receptor agonist administered as a weekly subcutaneous injection.\n\nTitrated from 2.5 mg\u002Fweek to a target of 10 mg\u002Fweek over 12 weeks, then maintained at the maximum tolerated dose for the remainder of the 52-week treatment period.",[9],[27],"Mounjaro",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"BEHAVIORAL","Structured Lifestyle Intervention","Guideline-directed AF management (rate\u002Frhythm control, anticoagulation by CHA2DS2-VASc).\n\nStructured lifestyle intervention: 500 kcal\u002Fday caloric deficit; exercise prescription of ≥150 min\u002Fweek moderate aerobic; smoking cessation and alcohol moderation counseling.",[16,9],null,{"type":35,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"SPONSOR_INVESTIGATOR","Yunlong Wang","Chief Physician, Professor,","100648063","phase-4-effect-of-tirzepatide-on-recurrence-of-atrial-fibrillation-after-catheter-ablation-in-obese-patients-100648063",false,"NCT07715929","Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients","Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients: A Multicenter, Randomized, Open-Label Trial","TEAR-AF","Inclusion Criteria:\n\n* Age ≥18 years and ≤75 years at the time of screening\n* Documented symptomatic paroxysmal AF or persistent AF, confirmed by 12-lead ECG, Holter monitoring, or cardiac monitoring device, with documented AF episode duration ≥7 days (for persistent AF) and total AF history duration ≤5 years\n* Body weight criteria (aligned with NMPA-approved tirzepatide indication) meeting at least one of the following:\n\nBMI ≥28.0 kg\u002Fm² (obesity threshold per Chinese criteria), OR BMI ≥24.0 kg\u002Fm² and \\\u003C28.0 kg\u002Fm² (overweight per Chinese criteria) with at least one weight-related comorbidity: hypertension, dyslipidemia, type 2 diabetes mellitus (T2DM), obstructive sleep apnea syndrome (OSAS), or atherosclerotic cardiovascular disease (ASCVD)\n\n* Failed response to or intolerance of at least one antiarrhythmic drug (AAD), or explicit patient preference for a rhythm control strategy\n* Undergoing catheter ablation for AF at a participating center, with confirmed successful restoration of sinus rhythm at the end of the procedure (as determined by the operator)\n* Willing and able to understand the study procedures, provide written informed consent, and comply with all protocol requirements including 12-month follow-up visits\n* Capable of performing basic physical activity (no absolute contraindication to moderate-intensity aerobic exercise)\n\nExclusion Criteria:\n\nCardiovascular Exclusion Criteria\n\n* Long-standing persistent AF: continuous AF duration ≥5 years prior to enrollment\n* Prior catheter ablation for AF or atrial flutter at any time\n* Left atrial anteroposterior diameter \\>55 mm (by transthoracic echocardiography at screening)\n* Left ventricular ejection fraction (LVEF) \\\u003C35% at screening\n* NYHA functional class III or IV heart failure\n* Significant structural heart disease: hypertrophic cardiomyopathy, valvular heart disease requiring intervention, congenital heart disease, myocarditis, or cardiac sarcoidosis\n* Acute coronary syndrome (ACS), ischemic stroke\u002FTIA, or major cardiac surgery within 6 months prior to screening\n\nTirzepatide-Specific Exclusion Criteria (per NMPA Prescribing Information)\n\n* Prior use of any GLP-1 receptor agonist (liraglutide, semaglutide, dulaglutide, exenatide, etc.) or GIP receptor agonist, or known hypersensitivity to tirzepatide or any excipient in the formulation\n* Personal or family (first-degree relative) history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma (MTC)\n* History of acute pancreatitis or chronic pancreatitis, or current symptomatic cholelithiasis or cholecystitis\n* Type 1 DM\n* Severe gastrointestinal disease including severe gastroparesis, inflammatory bowel disease, or any condition that would substantially impair gastrointestinal motility or absorption\n\nGeneral Exclusion Criteria\n\n* Use of any weight-loss medication (orlistat, phentermine, naltrexone\u002Fbupropion, or other anti-obesity agents) or participation in any weight-loss pharmacotherapy clinical trial within 3 months prior to screening\n* Severe hepatic insufficiency (Child-Pugh class C) or severe renal insufficiency (eGFR \\\u003C15 mL\u002Fmin\u002F1.73 m²)\n* Active malignancy (receiving systemic anti-cancer treatment or with life expectancy \\\u003C2 years due to malignancy)\n* Pregnancy, breastfeeding, or women of childbearing potential who are unwilling to use highly effective contraception throughout the study and for ≥1 month after the last dose of tirzepatide\n* Severe psychiatric disorder (schizophrenia, bipolar disorder, severe major depressive disorder) that would impair ability to comply with study procedures\n* Known allergy or sensitivity to adhesive patch materials (relevant to ECG monitoring patch components)\n* Any other condition that, in the opinion of the investigator, would make participation inadvisable or compromise the safety of the participant or the integrity of the study","ALL","18 Years","75 Years",{"count":50,"type":51},710,"ESTIMATED","INTERVENTIONAL",[54],"PHASE4","Obese patients with atrial fibrillation (AF) have a high recurrence rate after catheter ablation, even at experienced centers. Weight reduction improves post-ablation outcomes, but lifestyle measures alone are difficult to sustain. Tirzepatide, a once-weekly GIP\u002FGLP-1 dual receptor agonist, produces greater weight loss than GLP-1 monotherapy and may confer additional cardiometabolic benefits. This multicenter, randomized, open-label, parallel-group, superiority trial evaluates whether adding standardized tirzepatide treatment to a structured lifestyle intervention - compared with the lifestyle intervention alone - reduces AF recurrence within 1 year after ablation in obese patients.",[57,58,59],"Atrial Fibrillation","Obesity & Overweight","Catheter Ablation",[57,23,61],"GIP\u002FGLP-1 receptor agonist","NOT_YET_RECRUITING","2026-07-15",{"date":65,"type":66},"2026-07-21","ACTUAL",{"date":68,"type":51},"2026-09-01",{"date":70,"type":51},"2029-12-30",{"name":36,"class":6}]